UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000017891
Receipt number R000020727
Scientific Title Efficacy of triple therapy for Helicobacter pylori infection using amoxicillin and clarithromycin and TAK-438 (vonoprazan) which is a novel potassium-competitive acid blocker to the patients treated unsuccessfully with PPI, amoxicillin and clarithromycin.
Date of disclosure of the study information 2015/06/12
Last modified on 2016/01/27 16:07:21

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Efficacy of triple therapy for Helicobacter pylori infection using amoxicillin and clarithromycin and TAK-438 (vonoprazan) which is a novel potassium-competitive acid blocker to the patients treated unsuccessfully with PPI, amoxicillin and clarithromycin.

Acronym

Efficacy of the treatment with TAK-438 (vonoprazan)/AC regimen for Helicobacter pylori infection to the patients treated unsuccessfully with PPI/AC regimen.

Scientific Title

Efficacy of triple therapy for Helicobacter pylori infection using amoxicillin and clarithromycin and TAK-438 (vonoprazan) which is a novel potassium-competitive acid blocker to the patients treated unsuccessfully with PPI, amoxicillin and clarithromycin.

Scientific Title:Acronym

Efficacy of the treatment with TAK-438 (vonoprazan)/AC regimen for Helicobacter pylori infection to the patients treated unsuccessfully with PPI/AC regimen.

Region

Japan


Condition

Condition

Chronic gastritis

Classification by specialty

Gastroenterology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the new regimens for the eradication of Helicobacter pylori

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Eradication rate of TAK-438 (vonoprazan)/AC regimen. ITP and PP analysis

Key secondary outcomes

adverse events of TAK-438 (vonoprazan)/AC regimen


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

80 years-old >=

Gender

Male and Female

Key inclusion criteria

The patients with chronic gastritis who visited the outpatient clinic of Kagawa Prefectural Central Hospital or Fukuyama medical centre, and were found to be H. pylori-positive.

Key exclusion criteria

We excluded patients if they had previously undergone treatment for eradication of H. pylori or gastrectomy; were pregnant; had an allergy to penicillin; had used a PPI, H2 receptor antagonist, adrenocortical steroids, or non-steroidal anti-inflammatory drugs within the month preceding the study.

Target sample size

150


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Tomoki Inaba

Organization

Kagawa Prefectural Central Hospital

Division name

Department of Gastroenterology

Zip code


Address

Takamatsu, Kagawa, Japan

TEL

(+81)-87-811-3333

Email

t-inaba@chp-kagawa.jp


Public contact

Name of contact person

1st name
Middle name
Last name Tomoki Inaba

Organization

Kagawa Prefectural Central Hospital

Division name

Department of Gastroenterology

Zip code


Address

Takamatsu, Kagawa, Japan

TEL

(+81)-87-811-3333

Homepage URL


Email

t-inaba@chp-kagawa.jp


Sponsor or person

Institute

Kagawa Prefectural Central Hospital

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

香川県立中央病院 (香川県)、福山医療センター(広島県)、岡山大学病院 (岡山県)


Other administrative information

Date of disclosure of the study information

2015 Year 06 Month 12 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results

Finally, the eradication rate of H. pylori was 70.2% with a second-line regimen of TAK-438AC in patients for whom the firrst-line treatment with RAC failed. Our study shows promising results of H. pylori eradication with TAK-438-based triple therapy after proton pump inhibitor-based triple therapy failure, based on faster onset of increase in intragastric pH by TAK-438 (vonoprazan).

Aliment Pharmacol Ther 2016; 43: 166

Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2015 Year 01 Month 09 Day

Date of IRB


Anticipated trial start date

2015 Year 01 Month 15 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

No problem of safty


Management information

Registered date

2015 Year 06 Month 12 Day

Last modified on

2016 Year 01 Month 27 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020727


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name